The Glycogen Storage Disorders (GSD) drugs in development market research report provides comprehensive information on the therapeutics under development for Glycogen Storage Disorders (GSD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Glycogen Storage Disorders (GSD). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Glycogen Storage Disorders (GSD) and features dormant and discontinued products.
GlobalData tracks 14 drugs in development for Glycogen Storage Disorders (GSD) by 11 companies/universities/institutes. The top development phase for Glycogen Storage Disorders (GSD) is phase ii with four drugs in that stage. The Glycogen Storage Disorders (GSD) pipeline has 13 drugs in development by companies and one by universities/ institutes. Some of the companies in the Glycogen Storage Disorders (GSD) pipeline products market are: Golden Heart Flower, Papillon Therapeutics and Boehringer Ingelheim International.
The key targets in the Glycogen Storage Disorders (GSD) pipeline products market include Glucose 6 Phosphatase, Lysosome Associated Membrane Glycoprotein 2, and Glycogen Debranching Enzyme.
The key mechanisms of action in the Glycogen Storage Disorders (GSD) pipeline product include Glucose 6 Phosphatase Activator with three drugs in Phase III. The Glycogen Storage Disorders (GSD) pipeline products include two routes of administration with the top ROA being Intravenous and three key molecule types in the Glycogen Storage Disorders (GSD) pipeline products market including Gene Therapy, and Small Molecule.
Glycogen Storage Disorders (GSD) overview
Glycogen storage diseases (GSDs) constitute inherited inborn errors in carbohydrate metabolism, with clinical manifestations emerging from neonatal stages to adulthood. Typically, these disorders arise from deficiencies in specific enzymes crucial for glycogen breakdown, leading to abnormal glycogen accumulation in the liver or skeletal muscles. The incapacity to mobilize glucose from glycogen results in hypoglycemia and exercise-induced weakness, contributing to enduring complications. The intricate nature of these metabolic disruptions underscores the importance of understanding GSDs for timely diagnosis and management, addressing both immediate symptoms such as hypoglycemia, and long-term consequences like exercise-induced weakness.
For a complete picture of Glycogen Storage Disorders (GSD)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
